Rare Protocols
Breast
| Protocol | SWOG S1706 |
|---|---|
| Cancer Type: | Inflammatory Breast Cancer |
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
Please check out the rare protocol list to locate other studies within this disease site.
Endocrine/Neuroendocrine
| Protocol | Alliance A021804 |
|---|---|
| Cancer Type: | ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA |
A PROSPECTIVE, MULTI-INSTITUTIONAL PHASE II TRIAL EVALUATING TEMOZOLOMIDE VS. TEMOZOLOMIDE AND OLAPARIB FOR ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA
Please check out the rare protocol list to locate other studies within this disease site.
Gastrointestinal
| Protocol | SWOG S1922 |
|---|---|
| Cancer Type: | Small bowel Adenocarcinoma |
Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Please check out the rare protocol list to locate other studies within this disease site.
Genitourinary
| Protocol | Alliance A031702 |
|---|---|
| Cancer Type: | rare genitourinary tumors |
Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors
Please check out the rare protocol list to locate other studies within this disease site.
Head and Neck
| Protocol | NRG HN007 |
|---|---|
| Cancer Type: | NASOPHARYNGEAL CARCINOMA |
AN OPEN-LABEL, PHASE III STUDY OF PLATINUM-GEMCITABINE WITH OR WITHOUT NIVOLUMAB IN THE FIRST-LINE TREATMENT OF RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA
| Protocol | NRG HN001 |
|---|---|
| Cancer Type: | Nasopharyngeal Carcinoma |
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | SWOG S1701 |
|---|---|
| Cancer Type: | Thymic Carcinoma |
A Randomized Phase II Trial of Carboplatin-Paclitaxel with or Without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | EA3163 |
|---|---|
| Cancer Type: | Nasal and Paranasal Sinus Squamous Cell Carcinoma |
Phase II Randomized Trial of Neo-Adjuvant Chemo f/b Surgery and Post-Op Radiation vs Surgery and Post-Op Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)
| Protocol | NRG HN004 |
|---|---|
| Cancer Type: | Locoregionally Advanced Head and Neck Cancer |
Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin
Please check out the rare protocol list to locate other studies within this disease site.
Lung
| Protocol | NRG LU006 |
|---|---|
| Cancer Type: | MALIGNANT PLEURAL MESOTHELIOMA |
PHASE III RANDOMIZED TRIAL OF PLEURECTOMY/DECORTICATION PLUS
CHEMOTHERAPY WITH ORWITHOUT ADJUVANT HEMITHORACIC
INTENSITY-MODULATED PLEURAL RADIATION THERAPY (IMPRINT)
FOR MALIGNANT PLEURAL MESOTHELIOMA (MPM)
Please check out the rare protocol list to locate other studies within this disease site.
Rare
| Protocol | Alliance A091902 |
|---|---|
| Cancer Type: | ANGIOSARCOMA |
A MULTICENTER PHASE II TRIAL OF PACLITAXEL WITH AND WITHOUT NIVOLUMAB IN TAXANE NAÏVE, AND NIVOLUMAB AND CABOZANTINIB IN TAXANE PRETREATED SUBJECTS WITH ANGIOSARCOMA
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | Alliance A021804 |
|---|---|
| Cancer Type: | ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA |
A PROSPECTIVE, MULTI-INSTITUTIONAL PHASE II TRIAL EVALUATING TEMOZOLOMIDE VS. TEMOZOLOMIDE AND OLAPARIB FOR ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | SWOG S1706 |
|---|---|
| Cancer Type: | Inflammatory Breast Cancer |
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | SWOG S1922 |
|---|---|
| Cancer Type: | Small bowel Adenocarcinoma |
Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | Alliance A031702 |
|---|---|
| Cancer Type: | rare genitourinary tumors |
Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | EA3163 |
|---|---|
| Cancer Type: | Nasal and Paranasal Sinus Squamous Cell Carcinoma |
Phase II Randomized Trial of Neo-Adjuvant Chemo f/b Surgery and Post-Op Radiation vs Surgery and Post-Op Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)
| Protocol | SWOG S1701 |
|---|---|
| Cancer Type: | Thymic Carcinoma |
A Randomized Phase II Trial of Carboplatin-Paclitaxel with or Without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
| Protocol | NRG HN001 |
|---|---|
| Cancer Type: | Nasopharyngeal Carcinoma |
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
| Protocol | NRG HN004 |
|---|---|
| Cancer Type: | Locoregionally Advanced Head and Neck Cancer |
Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin
| Protocol | NRG HN007 |
|---|---|
| Cancer Type: | NASOPHARYNGEAL CARCINOMA |
AN OPEN-LABEL, PHASE III STUDY OF PLATINUM-GEMCITABINE WITH OR WITHOUT NIVOLUMAB IN THE FIRST-LINE TREATMENT OF RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | NRG LU006 |
|---|---|
| Cancer Type: | MALIGNANT PLEURAL MESOTHELIOMA |
PHASE III RANDOMIZED TRIAL OF PLEURECTOMY/DECORTICATION PLUS
CHEMOTHERAPY WITH ORWITHOUT ADJUVANT HEMITHORACIC
INTENSITY-MODULATED PLEURAL RADIATION THERAPY (IMPRINT)
FOR MALIGNANT PLEURAL MESOTHELIOMA (MPM)
Please check out the rare protocol list to locate other studies within this disease site.
Sarcoma
| Protocol | Alliance A091902 |
|---|---|
| Cancer Type: | ANGIOSARCOMA |
A MULTICENTER PHASE II TRIAL OF PACLITAXEL WITH AND WITHOUT NIVOLUMAB IN TAXANE NAÏVE, AND NIVOLUMAB AND CABOZANTINIB IN TAXANE PRETREATED SUBJECTS WITH ANGIOSARCOMA
Please check out the rare protocol list to locate other studies within this disease site.
Cancer clinical trials are research studies for developing better ways of detecting,
treating, and eventually preventing cancer. By taking part in a clinical trial,
you are among the first to receive new research treatments before they are widely
available. Your participation in a clinical trial will influence the future direction
of cancer care.
If you are interested in participating in a clinical trial, consult with your physician.
Please note: clinical trials are not risk free. Patients must explore the options
that are best for their individuals needs with the help of their physician.
